Silence Therapeutics (SLN) said Monday its phase 2 trial of divesiran to treat Polychthemia Vera, a form of blood cancer, met its primary endpoint of the proportion of patients achieving a dose response, defined as the absence of phlebotomy and hematocrit below 45% during weeks 18 and 36.
Around 88% of the patients achieved a dose response compared with 19% for placebo. The key secondary endpoint of phlebotomy rate from the beginning through week 36 was also met, with the mean number of phlebotomies per patient in the divesiran groups significantly reduced, according to a statement.
Divesiran was well-tolerated and safety was consistent with previous trials. The company will present full phase 2 data at an upcoming medical congress, according to the company.
Shares of Silence Therapeutics rose 26% on Monday.
Price: $15.03, Change: $+3.08, Percent Change: +25.77%